Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Minerva Neurosciences (Nasdaq:NERV) announced that management will participate in two investor events in New York: the Wells Fargo Healthcare Conference on Tuesday, September 8 for 1x1 meetings, and the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, including a fireside chat from 2:45–3:15 PM EDT.

A live webcast and replay of the Cantor fireside chat will be available in the events section of the company’s website. Minerva is a clinical-stage biopharma conducting a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences.

Wells Fargo Healthcare Conference
Date: Tuesday, September 8
Format: 1x1 meetings
Location: New York, NY

2026 Cantor Global Healthcare Conference
Date: Wednesday, September 9
Format: Fireside chat and 1x1 meetings
Time: 2:45 – 3:15 PM EDT
Location: New York, NY                                                                                                                                                                                           

If you are interested in meeting with the Minerva team during the conferences, please reach out to your respective conference representative.

The live webcast can be accessed in the events section of the Minerva Neurosciences website HERE. Access to the webcast replay will be available approximately two hours after the completion of the events and will be archived on the Company’s website.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.

Contacts:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
FAhlholm@minervaneurosciences.com

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

FAQ

When will Minerva Neurosciences (NERV) present at the Wells Fargo Healthcare Conference in 2026?

Minerva Neurosciences will participate in the Wells Fargo Healthcare Conference on Tuesday, September 8. According to Minerva Neurosciences, the company’s management will hold 1x1 investor meetings in New York, NY, providing investors an opportunity for direct discussions with management during the healthcare-focused event.

What is the schedule for Minerva Neurosciences (NERV) at the 2026 Cantor Global Healthcare Conference?

Minerva Neurosciences is scheduled for a fireside chat on Wednesday, September 9, from 2:45–3:15 PM EDT. According to Minerva Neurosciences, the company will also conduct 1x1 investor meetings in New York, NY, as part of the Cantor Global Healthcare Conference program.

How can investors access the Minerva Neurosciences (NERV) webcast for the Cantor Global Healthcare Conference?

Investors can access the live webcast through the events section of the Minerva Neurosciences website. According to Minerva Neurosciences, a webcast replay will be available about two hours after the events and will remain archived on the company’s website for later viewing.

Will a replay of Minerva Neurosciences’ (NERV) investor conference appearance be available online?

Yes, a replay will be available on the company’s website. According to Minerva Neurosciences, access to the webcast replay will begin roughly two hours after the completion of the events and will stay archived in the website’s events section for ongoing investor access.

What is Minerva Neurosciences (NERV) currently developing in its Phase 3 trial?

Minerva is conducting a confirmatory Phase 3 trial of roluperidone. According to Minerva Neurosciences, this trial targets negative symptoms of schizophrenia, aligning with the company’s focus on developing product candidates for central nervous system diseases such as schizophrenia-related conditions.

What type of company is Minerva Neurosciences (NERV) and what does it focus on?

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on CNS diseases. According to Minerva Neurosciences, it is developing product candidates to treat central nervous system disorders and is currently running a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia.